Artemisinin-Based Combination Therapy Versus Quinine or Other Combinations for Treatment of Uncomplicated Plasmodium falciparum Malaria in the Second and Third Trimester of Pregnancy: A Systematic Review and Meta-Analysis

Renée J Burger, Anna M van Eijk, Milena Bussink, Jenny Hill, Feiko O Ter Kuile, Renée J Burger, Anna M van Eijk, Milena Bussink, Jenny Hill, Feiko O Ter Kuile

Abstract

The World Health Organization recommends artemisinin-based combination therapies (ACTs) for the treatment of uncomplicated falciparum malaria in the second and third trimesters of pregnancy. We conducted a meta-analysis to compare efficacy, safety and tolerability of ACTs versus quinine and other non-ACT antimalarials. The median PCR-adjusted failure rate by days 28 to 63 in the non-ACT group was 6 (range 0-37) per 100 women, lower in the ACT group overall (pooled risk ratio [PRR] random effects, 0.41; 95% confidence interval [CI], 0.16-1.05; 6 trials), and significantly lower compared with oral quinine (PRR, 0.20; 95% CI, 0.08-0.49; 4 trials). There were no differences in fetal deaths and congenital abnormalities. Compared with quinine, artemisinin-based combinations therapies were associated with less tinnitus (PRR, 0.19; 95% CI, 0.03-1.11; 4 studies), dizziness (PRR, 0.64; 95% CI, 0.44-0.93; 3 trials), and vomiting (PRR, 0.33; 95% CI, 0.15-0.73; 3 trials). Artemisinin-based combination therapies are better than quinine in the second and third trimesters; their use should be encouraged among health workers.

Keywords: artemisinins; malaria; pregnancy; quinine; treatment.

Figures

Figure 1.
Figure 1.
PRISMA flow diagram. Abbreviation: ACTs, artemisinin-based combination therapies.
Figure 2.
Figure 2.
(A) Meta-analysis of PCR-adjusted parasitological treatment failure risk comparing artemisinin-based combination therapies (ACTs) vs. non-ACTs, stratified by comparator drug. (B) Meta-analysis of PCR-adjusted parasitological treatment failure risk comparing ACTs versus non-ACTs, stratified by geographical region. (Note: Because statistical programs cannot handle 0% treatment failure for both arms in meta-analysis, information from Bounyasong [10] was entered as 1/28 for each arm, to attain a balanced risk ratio (RR) of 1 [26].) The shaded areas around the estimates are proportional to the weight of each study in the analysis. Abbreviations: AM, artemether; AQ, amodiaquine; AS, artesunate; ATP, atovaquone-proguanil; AZ, azithromycin; CD, chlorproguanil-dapsone; CI, confidence interval; L, lumefantrine; MQ, mefloquine; Q, quinine; SP, sulfadoxine-pyrimethamine.
Figure 3.
Figure 3.
Polymerase chain reaction (PCR)-adjusted cure rates (proportions) after treatment with artemisinin-based combination therapies (ACTs) and non-ACTs for uncomplicated malaria in pregnancy. The number after the drug indicates the number of days the drug was given. The red dashed vertical bar indicates the 0.95 proportion mark, which is the cut-off recommended by the World Health Organization (WHO) as the minimum efficacy for antimalarial medicines to be adopted as part of national malaria programs [27]. Abbreviations: AM, artemether; AQ, amodiaquine; AS, artesunate; ATP, atovaquone-proguanil; AZ, azithromycin; CI, confidence interval; L, lumefantrine; MQ, mefloquine; Q, quinine; SP, sulfadoxine-pyrimethamine.
Figure 4.
Figure 4.
Mean birth weight (grams) of newborns born to artemisinin-based combination therapy (ACT) and non-ACT recipients. (Note: All participants in the study by Kalilani et al [11] received the same treatment again at least 4 weeks after the first treatment, regardless of whether they were parasitemic at that subsequent visit.) The shaded areas around the estimates are proportional to the weight of each study in the analysis. Abbreviations: AM, artemether; AQ, amodiaquine; AS, artesunate; ATP, atovaquone-proguanil; AZ, azithromycin; CD, chlorproguanil-dapsone; CI, confidence interval; L, lumefantrine; MQ, mefloquine; N, sample size; Q, quinine; SD, standard deviation; SP, sulfadoxine-pyrimethamine.
Figure 5.
Figure 5.
Other efficacy, safety, and tolerability outcomes and subgroup analyses by control drug. The Assumed control-group risk (ACR) represents the observed median risk (expressed per 100 women) and range for each subgroup in the control-drug arm. The range for the ACR is only provided to illustrate high‐ and low‐risk populations, whereas the median risk is illustrative of a population with a moderate risk. The Corresponding intervention-group risk ([CIR] 95% confidence interval [CI]) is the corresponding risk in the ACT group computed as the ACR × risk ratio ([RR] 95% CI) [28]. Heterogeneity relating to the extent that the RRs vary between subgroups are shown as the I2 statistic, which depicts the percentage of the between‐study or between subgroup heterogeneity that is attributable to variability in the effect, rather than sampling variation. The corresponding P value is based on the χ2 statistic. *The number in brackets depicts the number of studies that were excluded in the analysis because of 0 events in both arms. †Heterogeneity between subgroups (quinine vs other non-ACT as control drug): low birth weight I2 0%, P = .89; miscarriage or stillbirth I2 0%, P = .39; congenital abnormalities I2 0%, P = .48.

References

    1. Desai M, ter Kuile FO, Nosten F et al. . Epidemiology and burden of malaria in pregnancy. Lancet Infect Dis 2007; 7:93–104.
    1. World Health Organization. Guidelines for the Treatment of Malaria. Geneva: World Health Organization; 2006.
    1. World Health Organization. Guidelines for the Treatment of Malaria. 3rd ed Geneva: World Health Organization; 2015.
    1. World Health Organization. World Malaria Report 2014. Geneva: World Health Organization; 2014.
    1. Hill J, D'Mello-Guyett L, Hoyt J et al. . Women's access and provider practices for the case management of malaria during pregnancy: a systematic review and meta-analysis. PLoS Med 2014; 11:e1001688.
    1. AR Scientific INC. Quilaquin®, quinine sulfate, capsules USP, 324 mg. Available at: Accessed 13 June 2015.
    1. Kaye DK, Nshemerirwe R, Mutyaba TS, Ndeezi G. A randomized clinical trial comparing safety, clinical and parasitological response to artemether-lumefantrine and chlorproguanil-dapsone in treatment of uncomplicated malaria in pregnancy in Mulago hospital, Uganda. J Infect Dev Ctries 2008; 2:135–9.
    1. McGready R, Tan SO, Ashley EA et al. . A randomised controlled trial of artemether-lumefantrine versus artesunate for uncomplicated Plasmodium falciparum treatment in pregnancy. PLoS Med 2008; 5:e253.
    1. Piola P, Nabasumba C, Turyakira E et al. . Efficacy and safety of artemether-lumefantrine compared with quinine in pregnant women with uncomplicated Plasmodium falciparum malaria: an open-label, randomised, non-inferiority trial. Lancet Infect Dis 2010; 10:762–9.
    1. Bounyasong S. Randomized trial of artesunate and mefloquine in comparison with quinine sulfate to treat P. falciparum malaria pregnant women. J Med Assoc Thai 2001; 84:1289–99.
    1. Kalilani L, Mofolo I, Chaponda M et al. . A randomized controlled pilot trial of azithromycin or artesunate added to sulfadoxine-pyrimethamine as treatment for malaria in pregnant women. PLoS One 2007; 2:e1166.
    1. McGready R, Ashley EA, Moo E et al. . A randomized comparison of artesunate-atovaquone-proguanil versus quinine in treatment for uncomplicated falciparum malaria during pregnancy. J Infect Dis 2005; 192:846–53.
    1. McGready R, Brockman A, Cho T et al. . Randomized comparison of mefloquine-artesunate versus quinine in the treatment of multidrug-resistant falciparum malaria in pregnancy. Trans R Soc Trop Med Hyg 2000; 94:689–93.
    1. Mutabingwa TK, Muze K, Ord R et al. . Randomized trial of artesunate+amodiaquine, sulfadoxine-pyrimethamine+amodiaquine, chlorproguanal-dapsone and SP for malaria in pregnancy in Tanzania. PLoS One 2009; 4:e5138.
    1. Sowunmi A, Oduola AM, Ogundahunsi OA et al. . Randomised trial of artemether versus artemether and mefloquine for the treatment of chloroquine/sufadoxine-pyrimethamine-resistant falciparum malaria during pregnancy. J Obstet Gynaecol 1998; 18:322–7.
    1. Orton LC, Omari AA. Drugs for treating uncomplicated malaria in pregnant women. Cochrane Database Syst Rev 2008; CD004912.
    1. Malaria in Pregnancy Consortium. Malaria in Pregnancy Library. Available at: Accessed 2 April 2015.
    1. van Eijk AM, Hill J, Povall S, Reynolds A et al. . The Malaria in Pregnancy Library: a bibliometric review. Malar J 2012; 11:362.
    1. Liberati A, Altman DG, Tetzlaff J et al. . The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009; 6:e1000100.
    1. Higgins JP, Altman DG, Gotzsche PC et al. . The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343:d5928.
    1. Higgins JP, Deeks JJ. Selecting studies and collecting data. In: Higgins JP, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions: The Cochrane Collaboration. Chichester, England: John Wiley & Sons Ltd, 2011:151–83.
    1. DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials 2007; 28:105–14.
    1. Deeks JJ, Higgins JP, Altman DG. Analysing data and undertaking meta-analyses. In: Higgins JP, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions: The Cochrane Collaboration. Chichester, England: John Wiley & Sons Ltd, 2011:243–93.
    1. Ministry of Health Uganda, ORC Macro. Uganda HIV/AIDS Sero-behavioural Survey 2004–2005. Calverton, MD: Ministry of Health and ORC Macro, 2006.
    1. Ministry of Health Uganda, ICF International, Centers for Disease Control and Prevention, US Agency for International Development, WHO Uganda. Uganda AIDS Indicator Survey 2011. Kampala, Uganda: Ministry of Health Uganda, 2012.
    1. Higgins JP, Deeks JJ, Altman DG. Special topics in statistics. In: Higgins JP, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions: The Cochrane Collaboration. Chichester, England: John Wiley & Sons Ltd, 2011:481–524.
    1. World Health Organization. Antimalarial drug efficacy. Available at: Accessed 18 January 2015.
    1. Schunemann HJ, Oxman AD, Higgins JP et al. . Presenting results and ‘Summary of findings’ tables. In: Higgins JP, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions: The Cochrane Collaboration. Chichester, England: John Wiley & Sons Ltd, 2011:335–57.
    1. Muehlenbachs A, Nabasumba C, McGready R et al. . Artemether-lumefantrine to treat malaria in pregnancy is associated with reduced placental haemozoin deposition compared to quinine in a randomized controlled trial. Malar J 2012; 11:150.
    1. Dellicour S, Hall S, Chandramohan D, Greenwood B. The safety of artemisinins during pregnancy: a pressing question. Malar J 2007; 6:15.
    1. Smith Paintain L, Antwi GD, Jones C et al. . Intermittent screening and treatment versus intermittent preventive treatment of malaria in pregnancy: provider knowledge and acceptability. PLoS One 2011; 6:e24035.
    1. Thien HV, Kager PA, Sauerwein HP. Hypoglycemia in falciparum malaria: is fasting an unrecognized and insufficiently emphasized risk factor? Trends Parasitol 2006; 22:410–5.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe